Zhongzhi Pharmaceutical Holdings Limited logo

Zhongzhi Pharmaceutical Holdings Limited

3737.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

最新資料

HK$0.685

+HK$0.005 · +0.74%

8月24日 下午3:25 HKT

3737.HK公司概覽

盤中時間採用HKT。市場資料可能有所延遲。

公司概況

公司網站

Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.

產業
Drug Manufacturers - Specialty & Generic
部門
Healthcare
總部
CN
執行長
Ying Feng Lai
上市以來
2015年7月13日
僱員
2,284

市場位置

成交量
23.3萬
0.6× 平均值
平均成交量
38.75萬
日均成交量
市值
5.78億 HKD
貝塔
0.42
市場參考 1

財務數據

財務快照

最近十二個月

財務健康

奧特曼 Z 分數
3.71
皮奧特羅斯基 F 分數
6 共 9 個

財報歷史與展望

最新財年每股收益
0.021
2025會計年度 · 年增-81.36%
最新財年收入
17.37億 CNY
2025會計年度 · 年增-21.55%

年度每股收益趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估
年度每股收益趨勢0.210.140.07021會計年度22會計年度23會計年度24會計年度25會計年度

年度營收趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估
年度營收趨勢22.63億20.72億18.81億16.9億21會計年度22會計年度23會計年度24會計年度25會計年度

3737.HK同業公司

繼續GoAI的研究

在 GoAI 中研究3737.HK

research.disclaimer